First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Kaken Pharmaceutical: the story is balanced — Quarterly prescription volume trends for key products (Beselna, Duobrii) tracked through Japanese pharmacy dispensing…
value - The 2.1x P/S ratio and 1.1x P/B valuation suggest value orientation despite 30.5% revenue growth.
Low direct sensitivity given minimal debt (0.03 D/E ratio) and strong cash position (4.09 current ratio).
Watch on earnings: Japanese yen exchange rate (USD/JPY) affecting international royalty income translation and imported API costs, Japan pharmaceutical production index as proxy for domestic manufacturing activity and supply chain health, Japanese consumer confidence and retail sales for OTC dermatology product demand.
One Sentence Summary:
Kaken Pharmaceutical: the story is balanced — quarterly prescription volume trends for key products (beselna, duobrii) tracked through japanese pharmacy dispensing data.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.